home LATEST ONCOPRESCRIBE UPDATES Capivasertib Plus Fulvestrant Improves Progression Free Survival in Advanced Hormone Receptor Positive Breast CancerBRUKINSA® Superior to IMBRUVICA® in Relapsed/Refractory CLL/SLLNALIRIFOX Improves Overall Survival in Patients with Metastatic Pancreatic CancerBiomarkers May Predict Response to Enfortumab Vedotin in Advanced Urothelial CancerFDA Expands Adjuvant VERZENIO® Indication in High-Risk Early Breast CancerFive Year Outcomes with KEYTRUDA® Plus Chemotherapy in Metastatic Nonsquamous Non Small Cell Lung CancerOverall Survival Benefit with Pembrolizumab in Advanced Gastric CancerRucaparib or Physicians Choice of Therapy in Metastatic Prostate Cancer SHOW MORE FDAApprovals Meeting Updates Hem/OncUpdates Molecular Tidbits NEW REGIMENS ADDEDResearch RegimensTIBSOVO® - for Acute Myeloid Leukemia Single Agent LUMAKRAS® - for Non Small Cell Lung CancerKEYTRUDA® - for Malignant Melanoma TECENTRIQ® and ABRAXANE® - for Breast CancerKEYTRUDA® plus INLYTA® - for Renal Cancer Curbside ConsultationLung Cancer Special IssueImmuno-OncologyPrecision OncologyCOVID-19 Associated Coagulopathy: Diagnosis and ManagementTTP, HUS and aHUS: Different diseases – Different treatmentsHER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateDual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal TumorsFDA Approves ENDARI®, A New Treatment for Sickle Cell DiseaseSHOW MORE